Table 5 Top 20 significant HYPs for the PI3K inhibitor data set (GSE17785)
Mechanism | Direction | Correct | Richness | Concordance | Ambiguous | Contra | Possible | Observed |
|---|---|---|---|---|---|---|---|---|
a(CHEBI:lapatinib) | 1 | 21 | 1.5E-03 | 4.8E-07 | 0 | 0 | 72 | 21 |
tscript(p(HGNC:FOXO1)) | 1 | 43 | 2.2E-05 | 7.0E-06 | 0 | 11 | 208 | 54 |
tscript(p(HGNC:FOXO3)) | 1 | 34 | 1.6E-10 | 3.4E-05 | 0 | 8 | 103 | 42 |
a(SCHEM:Hydrocortisone) | 1 | 41 | 2.4E-07 | 4.1E-05 | 0 | 12 | 177 | 53 |
a(CHEBI:estradiol) | −1 | 36 | 1.4E-03 | 7.8E-05 | 0 | 10 | 199 | 46 |
a(SCHEM:“serum insulin”) | −1 | 46 | 1.5E-07 | 8.8E-05 | 0 | 16 | 217 | 62 |
kin(p(PFH:“PRKC Family”)) | −1 | 26 | 3.3E-02 | 1.5E-03 | 0 | 8 | 166 | 34 |
a(CHEBI:“nitric oxide”) | −1 | 29 | 8.2E-03 | 1.7E-03 | 0 | 10 | 178 | 39 |
path(SDIS:“lung adenocarcinoma”) | −1 | 20 | 1.3E-02 | 2.0E-03 | 0 | 5 | 106 | 25 |
bp(MESHPP:“Menstrual Cycle”) | 1 | 18 | 5.2E-03 | 2.2E-03 | 0 | 4 | 84 | 22 |
a(CHEBI:camptothecin) | −1 | 23 | 3.1E-04 | 5.3E-03 | 0 | 8 | 111 | 31 |
p(HGNC:AGT) | −1 | 23 | 1.1E-03 | 5.3E-03 | 0 | 8 | 119 | 31 |
tscript(p(HGNC:FOXO4)) | 1 | 7 | 5.6E-03 | 7.8E-03 | 0 | 0 | 16 | 7 |
tscript(p(HGNC:SP5)) | 1 | 17 | 3.2E-03 | 8.5E-03 | 0 | 5 | 81 | 22 |
a(CHEBI:androgen) | −1 | 35 | 8.0E-04 | 8.8E-03 | 0 | 17 | 226 | 52 |
bp(GO:“response to heat”) | −1 | 39 | 1.2E-05 | 9.2E-03 | 0 | 20 | 229 | 59 |
path(SDIS:“viral infection”) | 1 | 42 | 3.3E-08 | 1.2E-02 | 0 | 23 | 223 | 65 |
kin(complex(NCH:“p85/p110 PI3Kinase Complex”)) | −1 | 22 | 2.5E-06 | 1.5E-02 | 0 | 9 | 89 | 31 |
kin(p(PFH:“AKT Family”)) | −1 | 14 | 7.7E-05 | 1.5E-02 | 1 | 4 | 51 | 19 |
a(CHEBI:haloperidol) | −1 | 6 | 2.4E-02 | 1.6E-02 | 0 | 0 | 16 | 6 |